Microbio Co., Ltd. (TPEX:4128)
Taiwan · Delayed Price · Currency is TWD 18.45
-0.10 (-0.54%)
Feb 11, 2026, 1:30 PM CST
Microbio Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,777 | 1,672 | 1,554 | 1,690 | 1,745 | 1,572 |
Other Revenue | 81.57 | 51.23 | 37.47 | 31.44 | 37 | 29.18 |
| 1,858 | 1,723 | 1,591 | 1,722 | 1,782 | 1,601 | |
Revenue Growth (YoY) | 10.49% | 8.26% | -7.58% | -3.38% | 11.28% | 9.21% |
Cost of Revenue | 1,131 | 1,047 | 987.51 | 1,031 | 1,043 | 967.67 |
Gross Profit | 727.79 | 676.08 | 603.88 | 691.3 | 739.37 | 633.73 |
Selling, General & Admin | 785.14 | 738.84 | 705.86 | 536.69 | 1,041 | 1,387 |
Research & Development | 345.88 | 388.66 | 404.49 | 264.91 | 861.54 | 352.97 |
Other Operating Expenses | - | - | - | - | -0.35 | - |
Operating Expenses | 1,131 | 1,127 | 1,110 | 801.61 | 1,902 | 1,740 |
Operating Income | -403.23 | -451.42 | -506.47 | -110.31 | -1,163 | -1,106 |
Interest Expense | -11.1 | -10.13 | -7.38 | -6.1 | -6.22 | -7.33 |
Interest & Investment Income | 75.03 | 89.14 | 92.55 | 47.4 | 40.85 | 61.27 |
Earnings From Equity Investments | -841.51 | -933.23 | -1,052 | 235.94 | 719.45 | 1,652 |
Currency Exchange Gain (Loss) | 14.14 | 17.26 | 23.33 | 124.45 | -40.11 | -105.99 |
Other Non Operating Income (Expenses) | 4.62 | 8.32 | 5.31 | 8.7 | 14.45 | 27.32 |
EBT Excluding Unusual Items | -1,162 | -1,280 | -1,445 | 300.08 | -434.35 | 521.04 |
Gain (Loss) on Sale of Investments | -26.1 | -3.21 | 65.97 | 22.39 | -8.19 | 6.07 |
Gain (Loss) on Sale of Assets | 4.18 | 4.6 | -0.01 | -171.46 | -1.43 | -2.69 |
Asset Writedown | -1.51 | - | - | - | 3.7 | -6.45 |
Other Unusual Items | 0.49 | 0.27 | 0.98 | 0.82 | 208.4 | 1.45 |
Pretax Income | -1,185 | -1,278 | -1,378 | 151.83 | -231.87 | 519.42 |
Income Tax Expense | -0.18 | 0.17 | -0.55 | -0.6 | 1.29 | -0.42 |
Earnings From Continuing Operations | -1,185 | -1,279 | -1,377 | 152.42 | -233.16 | 519.84 |
Minority Interest in Earnings | 152.86 | 177.76 | 197.44 | 58.77 | 282.58 | 144.33 |
Net Income | -1,032 | -1,101 | -1,180 | 211.2 | 49.42 | 664.17 |
Net Income to Common | -1,032 | -1,101 | -1,180 | 211.2 | 49.42 | 664.17 |
Net Income Growth | - | - | - | 327.33% | -92.56% | - |
Shares Outstanding (Basic) | 588 | 588 | 588 | 588 | 573 | 547 |
Shares Outstanding (Diluted) | 588 | 588 | 588 | 588 | 573 | 547 |
Shares Change (YoY) | - | - | 0.05% | 2.55% | 4.78% | -4.46% |
EPS (Basic) | -1.75 | -1.87 | -2.01 | 0.36 | 0.09 | 1.21 |
EPS (Diluted) | -1.76 | -1.87 | -2.01 | 0.36 | 0.09 | 1.21 |
EPS Growth | - | - | - | 316.73% | -92.89% | - |
Free Cash Flow | 112.82 | 507.32 | -163.53 | 102.69 | -33.24 | 55.68 |
Free Cash Flow Per Share | 0.19 | 0.86 | -0.28 | 0.17 | -0.06 | 0.10 |
Dividend Per Share | - | - | - | 0.035 | 0.032 | - |
Dividend Growth | - | - | - | 9.43% | - | - |
Gross Margin | 39.16% | 39.24% | 37.95% | 40.15% | 41.49% | 39.57% |
Operating Margin | -21.70% | -26.20% | -31.83% | -6.41% | -65.25% | -69.06% |
Profit Margin | -55.53% | -63.89% | -74.14% | 12.27% | 2.77% | 41.47% |
Free Cash Flow Margin | 6.07% | 29.45% | -10.28% | 5.96% | -1.86% | 3.48% |
EBITDA | -304.29 | -350.3 | -408.42 | -11.91 | -1,033 | -1,032 |
EBITDA Margin | -16.38% | -20.33% | -25.66% | -0.69% | -57.95% | -64.42% |
D&A For EBITDA | 98.94 | 101.12 | 98.05 | 98.4 | 129.98 | 74.26 |
EBIT | -403.23 | -451.42 | -506.47 | -110.31 | -1,163 | -1,106 |
EBIT Margin | -21.70% | -26.20% | -31.83% | -6.41% | -65.25% | -69.06% |
Revenue as Reported | 1,858 | 1,723 | 1,591 | 1,722 | 1,782 | 1,601 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.